The GlaxoSmithKline Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

High impact company profile available at BioMarket

The Merger and Acquisition Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered into by the worlds leading biopharma companies

As more healthcare providers and payers realize the benefits of telehealth, technology vendors will need to understand where opportunities exist in the telehealth market.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of dental pain drugs by company and by stage as well as a summary of the latest news and developments in this area.

Halozyme Therapeutics Inc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

This report deals with the traditional scope of clinical immunoassay, while looking at the emerging technology trends in this sector.

Based on an analysis of 43 companies and 1,200+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of th

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of diabetic neuropathy drugs by company and by stage as well as a summary of the latest news and developments in this area.

A new report examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology.

Analysis of Bayer Schering Pharma’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see changes, but expansion. This expansion is based on increased general awareness

Provides analysis of recent events in the osteoarthritis disease area and their impact on the market. Includes an event-based, indication-specific ten year forecast of both pipeline and marketed products to 2017 in the seven major markets (7MM).

This report explores the future of the contract manufacturing market with a detailed analysis of emerging drivers and restraints, business models and production strategies.

Key issues in bone metastases, including mechanisms of normal and altered bone metabolism, epidemiology data, current treatment options, unmet needs, analysis of pipeline drugs in direct development for bone metastases and key stakeholder opinions.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of ulcerative colitis drugs by company and by stage as well as a summary of the latest news and developments in this area.

The Distribution Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.

"Analytical Tool - Targeted Therapeutics: Non-Small Cell Lung Cancer " offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in non-small cell lung cancer R&D and business development.

High impact company profile available at BioMarket

Orexigen Therapeutics Inc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

The Wyeth Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

An analysis of the market conditions driving the adoption of telehealth solutions.

High impact company profile available at BioMarket

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future CNS market trends and major growth opportunities. The data and ana

Danaher is a diversified technology company engaged in designing, manufacturing and marketing of professional, medical, industrial and consumer products with strong brand names and significant market positions.

This analysis examines the historical and forecast performance for Almirall in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sa

Quarterly briefings, delivered in a concise presentation format, enable our clients to access and share the content of our ongoing research programmes quickly and efficiently.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of gout drugs by company and by stage as well as a summary of the latest news and developments in this area.

Pharmaceuticals in Germany industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry.

Analysis of Bristol-Myers Squibb’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013